Hostname: page-component-78c5997874-4rdpn Total loading time: 0 Render date: 2024-11-10T05:23:09.962Z Has data issue: false hasContentIssue false
  • English
  • Français

Ertapenem Prophylaxis Associated With an Increased Risk of Clostridium difficile Infection Among Surgical Patients

Published online by Cambridge University Press:  17 August 2015

Seungwon Lee ,
Priya Prasad ,
Matthew Lin ,
Susan Garritson ,
Amy Nichols  and
Catherine Liu
Seungwon Lee
Affiliation:
Department of Hospital Epidemiology and Infection Control, University of California San Francisco Medical Center, San Francisco, California
Priya Prasad
Affiliation:
Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California
Matthew Lin
Affiliation:
Department of Surgery, University of California San Francisco, San Francisco, California
Susan Garritson
Affiliation:
Department of Hospital Epidemiology and Infection Control, University of California San Francisco Medical Center, San Francisco, California
Amy Nichols
Affiliation:
Department of Hospital Epidemiology and Infection Control, University of California San Francisco Medical Center, San Francisco, California
Catherine Liu*
Affiliation:
Division of Infectious Diseases, Department of Medicine, University of California San Francisco, San Francisco, California.
*
*Address correspondence to Catherine Liu, MD, Division of Infectious Diseases, University of California San Francisco, 513 Parnassus Ave, S380, San Francisco, CA 94143 (catherine.liu@ucsf.edu).
Get access Rights & Permissions [Opens in a new window]

Abstract

A case-control study was conducted to determine risk factors for hospital-onset Clostridium difficile infection among patients admitted to 2 surgical units. Ertapenem prophylaxis was significantly associated with C. difficile infection risk (odds ratio, 3.13 [95% CI, 1.13–8.68], P=.028) and may offer an antimicrobial stewardship target among surgical patients.

Infect. Control Hosp. Epidemiol. 2015;36(11):1351–1354

Type
Concise Communications
Information
Infection Control & Hospital Epidemiology , Volume 36 , Issue 11 , November 2015 , pp. 1351 - 1354
Copyright
© 2015 by The Society for Healthcare Epidemiology of America. All rights reserved 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

Presented in part: IDWeek 2014; Philadelphia, PA; October 8-12, 2014 (Abstract 1623).

References

REFERENCES

1. Magill, SS, Edwards, JR, Bamberg, W, et al. Multistate point-prevalence survey of health care-associated infections. N Engl J Med 2014;370:1198–1208.CrossRefGoogle ScholarPubMed
2. Gase, KA, Haley, VB, Xiong, K, Van Antwerpen, C, Stricof, RL. Comparison of 2 Clostridium difficile surveillance methods: National Healthcare Safety Network's laboratory-identified event reporting module versus clinical infection surveillance. Infect Control Hosp Epidemiol 2013;34:284–290.Google Scholar
3. Itani, KM, Wilson, SE, Awad, SS, Jensen, EH, Finn, TS, Abramson, MA. Ertapenem versus cefotetan prophylaxis in elective colorectal surgery. N Engl J Med 2006;355:2640–2651.Google Scholar
4. Invanz (ertapenem) [package insert and label information]. Whitehouse Station, NJ: Merck; 2011.Google Scholar
5. Bratzler, DW, Dellinger, EP, Olsen, KM, et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery. Am J Health Syst Pharm 2013;70:195–283.Google Scholar
6. Gaynes, R, Rimland, D, Killum, E, et al. Outbreak of Clostridium difficile infection in a long-term care facility: association with gatifloxacin use. Clin Infect Dis 2004;38:640–645.CrossRefGoogle Scholar
7. Wenisch, JM, Equiluz-Bruck, S, Fudel, M, et al. Decreasing Clostridium difficile infections by an antimicrobial stewardship program that reduces moxifloxacin use. Antimicrob Agents Chemother 2014;58:5079–5083.Google Scholar
8. Garneau, JR, Valiquette, L, Fortier, LC. Prevention of Clostridium difficile spore formation by sub-inhibitory concentrations of tigecycline and piperacillin/tazobactam. BMC Infect Dis 2014;14:29.Google Scholar
9. Settle, CD, Wilcox, MH, Fawley, WN, Corrado, OJ, Hawkey, PM. Prospective study of the risk of Clostridium difficile diarrhoea in elderly patients following treatment with cefotaxime or piperacillin-tazobactam. Aliment Pharmacol Ther 1998;12:1217–1223.Google Scholar